bevacizumab
Pronunciation: be-vuh-SIZ-uh-mab
Other Name(s): Avastin®; Mvasi®; Zirabev®; Bambevi®; Abevmy®; Aybintio®; Vegzelma™
Appearance: Clear, colourless solution mixed into larger bags of fluids
Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Drug Monograph
Nov 2024
Eligibility Forms
Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Bevacizumab (Biosimilar) - Metastatic (Stage IVB) Persistent or Recurrent Carcinoma of the Cervix Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma Bevacizumab (Biosimilar) - Metastatic Colorectal Small Bowel or Appendiceal Cancer Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent GlioblastomaPatient Info Sheet
Jul 2024
What it is used for
- For treating certain types of colorectal, lung, brain, ovarian, cervical, kidney and other cancers. It may be used alone or with other chemotherapy drugs, depending on the type of cancer.
- Bevacizumab is available as a biosimilar medication. See our biosimilar pamphlet for more information.